Virginia M. Stone
Huddinge, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Coxsackie B1 virus-like particle vaccine modified to exclude a highly conserved immunoreactive region from the capsid induces potent neutralizing antibodies and protects against infection in mice.
Journal: Journal of biomedical science
Published: June 18, 2025
Frequent longitudinal blood microsampling and proteome monitoring identify disease markers and enable timely intervention in a mouse model of type 1 diabetes.
Journal: Diabetologia
Published: February 04, 2025
Proteome profiling of whole plasma and plasma-derived extracellular vesicles facilitates the detection of tissue biomarkers in the non-obese diabetic mouse.
Journal: Frontiers in endocrinology
Published: June 16, 2022
Inhibition of Type III Interferon Expression in Intestinal Epithelial Cells-A Strategy Used by Coxsackie B Virus to Evade the Host's Innate Immune Response at the Primary Site of Infection?
Journal: Microorganisms
Published: October 29, 2020
Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine.
Journal: Microorganisms
Published: July 04, 2020
Antibody Responses against Enterovirus Proteases are Potential Markers for an Acute Infection.
Journal: Viruses
Published: November 12, 2019
A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates.
Journal: Science advances
Published: August 26, 2019
Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine.
Journal: Antiviral research
Published: June 20, 2019
A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine.
Journal: Vaccine
Published: March 22, 2019
Last Updated: 09/26/2026